Intellia Therapeutics (NASDAQ:NTLA) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald restated their overweight rating on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a research note published on Monday morning, Benzinga reports. The firm currently has a $65.00 price objective on the stock. Several other research firms have also commented on NTLA. BMO Capital Markets raised their price target on shares of […]
More Stories
Elementis (OTCMKTS:ELMTY) Hits New 52-Week High – Here’s What Happened
Elementis plc (OTCMKTS:ELMTY – Get Free Report) shares reached a new 52-week high on Monday . The stock traded as...
iShares Short Duration Bond Active ETF (BATS:NEAR) Hits New 1-Year High – What’s Next?
iShares Short Duration Bond Active ETF (BATS:NEAR – Get Free Report) hit a new 52-week high on Monday . The...
Nuveen ESG Large-Cap Growth ETF (BATS:NULG) Reaches New 1-Year High – Should You Buy?
Nuveen ESG Large-Cap Growth ETF (BATS:NULG – Get Free Report) reached a new 52-week high during trading on Monday ....
Scout24 (ETR:G24) Sets New 52-Week High – Here’s Why
Scout24 SE (ETR:G24 – Get Free Report) shares hit a new 52-week high during trading on Monday . The company...
iShares MSCI USA Value Factor ETF (BATS:VLUE) Hits New 12-Month High – Time to Buy?
iShares MSCI USA Value Factor ETF (BATS:VLUE – Get Free Report)’s share price hit a new 52-week high during mid-day...
iShares MSCI Chile ETF (BATS:ECH) Reaches New 12-Month Low – Time to Sell?
iShares MSCI Chile ETF (BATS:ECH – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on...